At one point, it was Europe's most valuable company. Now, as Danish pharmaceutical group Novo Nordisk prepares to publish its third-quarter earnings on Wednesday, the picture looks very different. CNBC's Charlotte Reed will travel to Copenhagen to speak with the company's new CEO Mark Doustdar, a 30-year veteran of the company, who has been in the top job since August. It's not been an easy ride so far, with the group announcing a sharp decline in sales, pressure on profit, a round of jobs cuts